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AbsTrACT
background Frontotemporal dementia (FtD) is a 
pathologically heterogeneous neurodegenerative disorder 
associated usually with tau or tDp-43 pathology, although 
some phenotypes such as logopenic variant primary 
progressive aphasia are more commonly associated with 
Alzheimer’s disease pathology. Currently, there are no 
biomarkers able to diagnose the underlying pathology 
during life. In this study, we aimed to investigate the 
potential of novel tau species within cerebrospinal fluid 
(CSF) as biomarkers for tau pathology in FtD.
Methods 86 participants were included: 66 with 
a clinical diagnosis within the FtD spectrum and 20 
healthy controls. Immunoassays targeting tau fragments 
N-123, N-mid-region, N-224 and X-368, as well as a 
non-phosphorylated form of tau were measured in CSF, 
along with total-tau (t-tau) and phospho-tau (p-tau(181)). 
patients with FtD were grouped based on their Aβ42 
level into those likely to have underlying Alzheimer’s 
disease (AD) pathology (n=21) and those with likely 
frontotemporal lobar degeneration (FtLD) pathology 
(n=45). the FtLD group was then subgrouped based on 
their underlying clinical and genetic diagnoses into those 
with likely tau (n=7) or tDp-43 (n=18) pathology.
results Significantly higher concentrations of tau N-mid-
region, tau N-224 and non-phosphorylated tau were seen 
in both the AD group and FtLD group compared with 
controls. however, none of the novel tau species showed 
a significant difference between the AD and FtLD groups, 
nor between the tDp-43 and tau pathology groups. In a 
subanalysis, normalising for total-tau, none of the novel 
tau species provided a higher sensitivity and specificity 
to distinguish between tau and tDp-43 pathology than 
p-tau(181)/t-tau, which itself only had a sensitivity of 61.1% 
and specificity of 85.7% with a cut-off of <0.109.
Conclusions Despite investigating multiple novel CSF 
tau fragments, none show promise as an FtD biomarker 
and so the quest for in vivo markers of FtLD-tau 
pathology continues.
INTroduCTIoN
Frontotemporal dementia (FTD) is a common form of 
early-onset dementia, but it is pathologically hetero-
geneous, which precludes accurate diagnosis during 
life of the underlying molecular cause.1 The majority 
of patients with FTD have either tau or TDP-43 
inclusions at post mortem, but at present there are 
no biomarkers that can reliably separate these groups 
from each other or from healthy controls. Currently 
available cerebrospinal fluid (CSF) measures of tau 
do not seem to represent the burden of cerebral 
tau pathology and are variably affected in different 
forms of FTD. Furthermore, they can be abnormal 
in other proteinopathies.2–5 However, studies indi-
cate that the tau protein can be cleaved into multiple 
different fragments, which are actively secreted from 
cells and can therefore potentially be identified in 
CSF.6 7 In this study, we assessed the potential of 
novel CSF measures of different tau species as candi-
date biomarkers for FTD.
MeThods
Participants
86 consecutively recruited participants with avail-
able CSF from the University College London 
FTD cohort studies were included in the study: 66 
patients and 20 healthy cognitively normal controls. 
The 66 patients met consensus diagnostic criteria 
for either behavioural variant FTD (bvFTD) (21, 
of whom one patient had associated motor neuron 
disease)8 or primary progressive aphasia (PPA)9 
(45). In the PPA cohort, 11 had semantic variant, 16 
had non-fluent variant (of whom two patients had 
associated progressive supranuclear palsy), 15 had 
logopenic variant and 3 did not meet criteria for 
any of the three variants, named PPA-not otherwise 
specified (PPA-NOS).9 All patients were screened 
for mutations causative of FTD and 10 patients 
were found to have a pathogenic mutation: MAPT 
(4), GRN (3) and C9orf72 (3).
Measurement of CsF markers
CSF was collected, processed and stored at −80°C 
according to standardised procedures.10 11 Initially, 
the concentrations of the currently available markers 
of CSF T-tau, P-tau(181) and Aβ42 were determined 
using sandwich ELISAs (INNOTEST; Fujirebio 
Europe N.V., Gent, Belgium) following manufactur-
er’s instructions.
We then performed five further ELISAs, one 
previously reported to identify non-phosphorylated 
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Figure 1 (A) Schematic of tau 441 aa protein with the approximate location of various linear epitope antibodies in the different immunoassays. Innotest 
t-tau uses At120 (224 aa) as the capture antibody and a combination of ht7 (159–163 aa) and Bt2 (194–198 aa) for detection. p-tau(181) uses ht7 to 
capture the protein and At270 (phosphorylated 181 aa) as detection. N-123 and N-224 use in-house developed tau N-123 (123 aa) and tau N-224 (224 
aa) as capture antibodies, respectively, and tau 12 (9 aa) as detection. N-Mid-region captures tau using tau 12 and detects it with a combination of ht7 and 
Bt2. X-368 uses tau 368 (368 aa) as a capture antibody and K9JA (243–441 aa) as detection. Nonphosphorylated tau uses 1G2 as a capture (binds to the 
non-phosphorylated peptide sequences Kttp (174–177 aa), Kttp (180–183 aa) and rttp (230–233 aa)) and 7e5 (156–165 aa) as detection. *represents 
polyclonal antibodies, and consequently the dotted lines represent approximate epitope location. (B) Comparison of t-tau (pg/ml), p-tau(181), tau N-123, 
tau N-mid-region, tau N-224, Non-p-tau and tau X-368 between patients with Aβ42<550pg/ml and >550pg/ml and healthy controls. horizontal bars 
show mean and standard deviation. Colours in graph: blue: behavioural variant FtD (bvFtD); green: nonfluent variant ppA (nfvppA); red: logopenic variant 
ppA (lvppA); brown: semantic variant ppA (svppA); pink: patients with a not otherwise specified variant of ppA (ppA-NoS). (C) Comparison of t-tau (pg/
ml), p-tau(181), tau N-123, tau N-mid-region, tau N-224, Non-p-tau and tau X-368 between patients with probable tau and tDp-43 pathology and healthy 
controls. Colours in graph: yellow: FtDMND; green: C9orf72 expansion mutation carriers; purple: svppA; teal: GrN mutation carriers; red: MApt mutation 
carriers; brown: corticobasal degeneration (CBD); blue: ppA-pSp: patients with ppA and progressive supranuclear palsy. (D) Comparison of p-tau(181)/t-tau, 
tau N-123/t-tau, tau N-midregion/t-tau, tau N-224/t-tau, Non-p-tau/t-tau and tau X-368/t-tau between patients with probable tau and tDp-43 pathology 
and healthy controls. Colours in graph: yellow: FtD-MND; green: C9orf72 expansion mutation carriers; purple: svppA; teal: GrN mutation carriers; red: MApt 
mutation carriers; brown: corticobasal degeneration (CBD); blue: ppA-pSp: patients with ppA and progressive supranuclear palsy. (e) Spearman’s correlation 
matrix between markers in a double gradient scale (pink, r=0; red, r=1). the p-value was less than 0.05 for all group comparisons.
forms of tau (performed as in Lewczuk et al12), and four novel 
assays (figure 1A; online supplementary material):
 ► Tau N-123 amino acid (aa): Plates were coated and incu-
bated overnight at +4˚C with in-house antibody anti-tau 
123. Titrated calibrators (123 recombinant tau fragment) 
and sample were co-incubated with biotinylated detection 
antibody Tau 12 (Nordic Biosite). For detection, enhanced 
streptavidin–horseradish peroxidase (HRP) complex was 
used.
 ► Tau N-224aa: Magnetic beads (Quanterix, Lexington, 
Massachusetts, USA) were conjugated with the capture 
antibody anti-Tau 224 according to bead supplier’s 
conjugation protocol. Prior to each run, Tau 224 recom-
binant protein calibrator was serially diluted and the 
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Table 1 Demographics and tau CSF marker concentrations for healthy controls, groups split by Duits criteria for likely AD pathology (vs FTLD 
pathology) and groups split by likely FTLD-tau and FTLD-TDP-43 pathology
healthy control Aβ42<550 µL Aβ42>550 µL Probable tau pathology
Probable TdP-43 
pathology
N 20 21 45 7 18
Male gender
N (% group)
10 (50.0) 11 (52.3) 34 (75.5) 5 (71.4) 13 (72.2)
Age at CSF (years)
Mean (SD)
64.2 (6.9) 65.8 (6.1) 64.1 (6.6) 64.8 (8.8) 62.3 (5.9)
T-tau pg/mL 
Mean (SD)
326.6 (90.8) 722.7 (529.1) 464.7 (344.1) 444.4 (146.4) 457.1 (224.6)
P-tau(181) pg/mL
Mean (SD)
51.1 (11.9) 72.1 (42.3) 51.3 (24.1) 53.5 (13.9) 47.2 (16.5)
Tau N-123 pg/mL
Mean (SD)
85.8 (115.7) 77.4 (77.4) 74.0 (82.5) 54.9 (53.5) 70.6 (87.0)
Tau N-mid-region pg/mL
Mean (SD)
153.4 (63.8) 294.7 (179.2) 216.7 (132.6) 215.4 (71.4) 235.1 (123.3)
Tau N-224 pg/mL
Mean (SD)
6.0 (3.4) 10.8 (8.2) 9.3 (8.2) 13.9 (13.1) 8.5 (4.7)
Non-phosphorylated tau pg/mL
Mean (SD)
39.4 (17.6) 77.2 (53.4) 57.0 (35.7) 51.4 (20.7) 62.5 (32.9)
Tau X-368 pg/mL
Mean (SD)
16.0 (4.1) 16.3 (6.3) 15.2 (4.8) 15.1 (2.9) 15.6 (4.1)
AD, Alzheimer's disease; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration.
biotin-labelled antibody Tau 12 (Nordic Biosite) was used 
for detection.
 ► Tau X-368aa: Magnetic beads (Quanterix) were conjugated 
with capture antibody anti-Tau368. Tau 1–368 recombinant 
protein was serially diluted and used as calibrator. As detec-
tion antibody, biotin-labelled K9JA (Sigma) was used.
 ► Tau N-mid-region: Tau12 (Nordic Biosite, binding region 
aa9–18) was used as coating antibody and, as for detection, 
a combination of biotinylated HT7 (Thermo Scientific, 
aa159–163) and BT2 (Thermo Scientific, aa194–198). For 
detection, enhanced streptavidin–HRP complex was used. 
Full-length recombinant Tau 441 2N4R (rPeptide) was used 
as calibrator.
statistical analysis
Concentrations of tau species were compared between groups 
using a linear regression model in STATA V.14 (StataCorp, 
College Station, Texas, USA) with 95% bias-corrected boot-
strapped CIs with 1000 repetitions. There was no difference in 
age and gender between controls and each of the disease groups 
(all comparisons >0.05; Kruskal-Wallis test, age; Fisher’s exact 
test, gender). The optimal cut-off point for each tau marker 
to differentiate tau from TDP-43 pathology was identified by 
selecting the concentration that produced the highest Youden 
index (J=sensitivity+specificity–1) using GraphPad Prism V.7 
(GraphPad Software, San Diego, California, USA). The area 
under the curve (AUC) was calculated for each comparison. 
Spearman’s correlation coefficient (ρ) was used to investigate 
the association between tau species.
resuLTs
Comparison of those with likely Ad versus FTLd pathology 
(figure 1b, table 1, online supplementary table)
Some patients with bvFTD or PPA (particularly the logopenic 
variant) may have underlying Alzheimer’s disease (AD) 
pathology rather than frontotemporal lobar degeneration 
(FTLD) pathology. The initial analysis therefore aimed to 
compare these groups with controls. We used the Duits 
criteria13 to identify those patients who were likely to have 
underlying AD pathology (i.e. CSF concentrations of Aβ42 
<550 pg/mL). This atypical AD group of 21 patients included 
14 with logopenic variant PPA, 3 with non-fluent variant PPA, 
1 with semantic variant PPA, 1 with PPA-NOS and 2 with 
bvFTD. Forty-five patients had Aβ42 >550 pg/mL and there-
fore were included in the FTLD group figure 2.
The mean (SD) T-tau and P-tau(181) concentrations were 
significantly higher in the AD group (722.7 (529.1) pg/mL; 
72.1 (42.3) pg/mL) compared with healthy controls (326.6 
(90.8) pg/mL; 51.1 (11.9) pg/mL) and the FTLD group (464.7 
(344.1) pg/mL; 51.3 (24.1) pg/mL).
The AD group also showed significantly higher concentrations 
than controls for tau N-mid-region (AD, 294.7 (179.2) pg/mL; 
controls, 153.4 (63.8) pg/mL), tau N-224 (10.8 (8.2) pg/mL; 6.0 
(3.4) pg/mL) and non-phosphorylated tau (77.2 (53.4) pg/mL; 
39.4 (17.6) pg/mL). However, no significant differences were 
seen for tau N-123 (77.4 (77.4) pg/mL; 85.8 (115.7) pg/mL) or 
tau X-368 (16.3 (6.3) pg/mL; 16.0 (4.1) pg/mL).
The FTLD group showed significantly higher concentra-
tions than controls for N-mid-region (216.7 (132.6) pg/mL), 
tau N-224 (9.3 (8.2) pg/mL) and non-phosphorylated tau 
(57.0 (35.7) pg/mL) but not for other novel measures.
None of the novel measures showed a significant difference 
between the AD and FTLD group.
Comparison of those with likely FTLd-tau versus FTLd-TdP-43 
pathology (figures 1C and d; table 1, online supplementary 
table)
Individuals in the FTLD group were then grouped based on 
their likely underlying pathology into an FTLD-tau group 
(containing MAPT mutation carriers, those with a secondary 
clinical diagnosis of progressive supranuclear palsy, and one 
patient with bvFTD who had subsequently come to post 
mortem and was found to have corticobasal degeneration; 
n=7) and an FTLD-TDP-43 group (containing GRN and 
C9orf72 mutation carriers, those with a primary clinical 
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Figure 2 Flow diagram of participants included in the analysis. AD, Alzheimer’s disease; CBD, corticobasal degeneration; FtD, frontotemporal dementia; 
FtLD, frontotemporal lobar degeneration; pSp, progressive supranuclear palsy; svppA, semantic variant primary progressive aphasia.
diagnosis of semantic variant PPA or a secondary diagnosis of 
motor neuron disease; n=18) (figure 2).
CSF T-tau concentrations were significantly higher in the 
FTLD-TDP-43 group (457.1 (224.6) pg/mL) compared with 
controls, and also in the FTLD-tau group (444.4 (146.4) pg/mL) 
compared with controls.
Tau N-mid-region (235.1 (123.3) pg/mL), tau N-224 (8.5 
(4.7) pg/mL) and non-phosphorylated tau (62.5 (32.9) pg/mL) 
also showed higher concentrations in the FTLD-TDP-43 group 
compared with healthy controls, while only concentrations of 
tau N-mid-region (215.4 (71.4) pg/mL) and tau N-224 (13.9 
(13.1) pg/mL) were significantly higher in the FTLD-tau group 
compared with controls. No significant differences were seen for 
tau N-123 and tau X-368.
None of the measures showed a significant difference between 
the FTLD-TDP-43 and FTLD-tau groups.
We performed a subanalysis normalising tau markers 
for T-tau, based on previous literature which has shown an 
improved differentiation of tau and TDP-43 pathology using 
the ratio of P-tau(181) to T-tau.
3–5 The P-tau(181)/T-tau ratio 
was significantly lower for both the FTLD-TDP-43 group 
(mean (SD) 0.113 (0.032)) and the FTLD-tau group (0.126 
(0.033)) compared with controls (0.160 (0.027)), but there 
was no significant difference between the FTLD-tau and 
FTLD-TDP-43 groups. Receiver operating characteristic 
(ROC) curve analysis measuring the ability of P-tau(181)/T-tau to 
differentiate probable FTLD-tau from FTLD-TDP-43 showed 
a sensitivity of 61.1% and specificity of 85.7% with a cut-off 
point of <0.109 and an AUC 0.63.
Of the novel tau species, both tau X-368 and tau N-224 had 
a significantly different ratio in the FTLD-tau group (mean 
(SD): 0.036 (0.010); 0.035 (0.037)) compared with controls 
(0.050 (0.009); 0.013 (0.009)). For tau X-368, the ratio 
was also lower in the FTLD-TDP-43 group (0.039 (0.013)) 
compared with controls, but there was no difference between 
the FTLD-tau and FTLD-TDP-43 groups. For tau N-224, there 
was also a significantly higher ratio for FTLD-tau compared 
with the FTLD-TDP-43 group (0.019 (0.010)). However, 
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sensitivity and specificity of tau N-224 ratio to differentiate 
between likely FTLD-tau and FTLD-TDP-43 groups was only 
61.1% and 57.1% with a cut-off point of <0.019 (AUC of 
0.63). No significant differences were shown in the other 
novel tau measures.
Correlations of tau CsF biomarkers
All CSF tau markers were significantly correlated with each other 
figure 1E. However, the strongest correlations were for T-tau 
with P-tau(181) (ρ=0.87) and tau N-mid-region (ρ=0.84), and for 
tau N-mid-region with tau X-368 (ρ=0.86) and non-phosphory-
lated tau (ρ=0.85). Although significant, the correlations of Tau 
N-123 with the other tau species were fairly weak.
dIsCussIoN
In this study, we investigated the potential of novel CSF tau 
measures as biomarkers of tau pathology in FTD. However, 
no significant differences were seen between those with likely 
underlying AD pathology and FTLD pathology, or between 
those with likely FTLD-tau and FTLD-TDP-43 pathology.
Tau N-224 was one of only two markers higher in the 
FTLD-tau group compared with controls, and when normalised 
for total-tau, showed a significant difference between 
FTLD-tau and FTLD-TDP-43, but separated the groups with 
only poor sensitivity and specificity of <65% (AUC of 0.63). 
A similar sensitivity (61.1%) and higher specificity (85.7%) 
was found for the P-tau(181)/T-tau ratio at a cut-off point of 
<0.109 (AUC of 0.63), a marker previously described by other 
groups: Hu et al3 found a sensitivity of 82% and specificity 
of 62% for the comparison of FTLD-tau and FTLD-TDP-43 
with a cut-off point of <0.372 (AUC of 0.73), while Borroni 
et al4 found 83% and 64% with a ratio of <0.136 (AUC of 
0.87), and Meeter et al5, 67% and 76% with a cut-off point of 
<0.121 (AUC of 0.73). However, such a sensitivity and speci-
ficity would have limited clinical use as it would still result in 
considerable overlap between groups.
Although the fragments we have measured do not show a diag-
nostic accuracy that is superior to the existing tau biomarkers, 
we find different patterns in the concentrations of the fragments 
between the pathological groups. This finding is in concordance 
with other studies which suggest that tau may be differentially 
processed and secreted in a regulated manner.14 We hypothe-
sise that specific tau fragments may be generated and secreted in 
different tauopathies, and here we provide evidence that three tau 
fragments are significantly increased in CSF in FTD compared 
with controls. It is likely that there are other fragments of tau, not 
analysed in this study, that are more specific to FTD, and further 
work is required to identify these.
This study has a number of limitations. The majority of the 
patients did not have pathological confirmation of the cause of 
their illness, and in addition, although there is a relatively large 
number of cases for a study of a rare disorder like FTD, the indi-
vidual numbers are small in each subgroup. There are also poten-
tially limitations in the assay sensitivities for the novel tau fragments 
such that improvement in these may lead to a clearer difference 
between cases and controls that is not currently apparent.
In conclusion, while a number of these novel tau species show 
significantly higher concentrations in those with underlying AD 
pathology, they do not show any added benefit above current 
tau biomarkers and are not useful as biomarkers of tau pathology 
in FTD. Further work in the development of biomarkers of tau 
and TDP-43 in FTD is needed, particularly in light of potential 
disease-modifying tau therapies currently entering clinical trials.
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